Want to join the conversation?
Pharmaceutical company $ALXN delivered total YoverY revenue growth of 18% and volume growth of 23% in 2Q16, driven by the strength of its three marketed therapies. Soliris grew with a steady number of new patients with PNH and aHUS being treated globally. Strensiq is a new driver of growth and Kanuma continued to progress.
$NFLX a monster move, going up. Expect making some money on Monday.
$AMD down more than 6% even after posting above consensus third quarter results.
$MCD stock rose more than 2% after it posted better than expected 3Q16 results, driven by global same-store sales growth. Meanwhile, earnings and revenue were lower than last year, hurt by refranchising efforts.